Cue Biopharma, Inc.
CUE
$0.7767
$0.00831.08%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -13.45% | 58.86% | 92.33% | 818.18% | 1,105.96% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -13.45% | 58.86% | 92.33% | 818.18% | 1,105.96% |
| Cost of Revenue | -27.46% | -5.49% | -10.52% | 8.60% | 67.56% |
| Gross Profit | 29.64% | 25.15% | 25.85% | 7.84% | -47.71% |
| SG&A Expenses | -29.27% | -17.12% | -17.37% | 0.24% | -71.25% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -27.69% | -9.40% | -12.47% | 6.03% | 3.06% |
| Operating Income | 29.59% | 21.95% | 23.19% | 5.32% | 8.13% |
| Income Before Tax | 29.31% | 21.31% | 22.86% | 5.81% | 7.94% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 29.31% | 21.31% | 22.86% | 5.81% | 7.94% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 29.31% | 21.31% | 22.86% | 5.81% | 7.94% |
| EBIT | 29.59% | 21.95% | 23.19% | 5.32% | 8.13% |
| EBITDA | 29.72% | 21.95% | 23.14% | 4.80% | 7.63% |
| EPS Basic | 55.06% | 28.81% | 31.12% | 14.99% | 23.58% |
| Normalized Basic EPS | 54.55% | 28.03% | 31.10% | 14.99% | 24.58% |
| EPS Diluted | 55.06% | 28.81% | 31.12% | 14.99% | 23.58% |
| Normalized Diluted EPS | 54.55% | 28.03% | 31.10% | 14.99% | 24.58% |
| Average Basic Shares Outstanding | 57.30% | 10.51% | 12.00% | 10.78% | 20.46% |
| Average Diluted Shares Outstanding | 57.30% | 10.51% | 12.00% | 10.78% | 20.46% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |